Compensatory roles of Protein Related to DAN and Cerberus (PRDC) decrease in pulmonary arterial hypertension.

Area of Science:

• Cardiovascular Biology
• Pulmonary Hypertension Pathophysiology
• Molecular Medicine

Background:

• Bone morphogenetic protein (BMP) signaling is often suppressed in pulmonary arterial hypertension (PAH).
• The compensatory mechanisms behind BMP signaling suppression in PAH remain unclear.
• PRDC, an antagonist of BMPs, is investigated for its role in PAH.

Purpose of the Study:

• To investigate the role of PRDC in pulmonary arterial hypertension (PAH).
• To elucidate the underlying mechanisms of PRDC's involvement in PAH.
• To evaluate the therapeutic potential of PRDC in PAH.

Main Methods:

• Analysis of PRDC and BMP cascade in human and rat hypertensive lungs and dPASMCs.
• In vitro cell experiments assessing BMP2/4 effects on dPASMCs and PRDC's reversal.
• In vivo studies involving PRDC supplementation in a rat model of PAH.

Main Results:

• PRDC and BMP cascade were decreased in hypertensive lungs.
• BMP2/4 inhibited dPASMCs proliferation, migration, and promoted apoptosis; PRDC reversed these effects.
• PRDC supplementation worsened PAH in rats, impacting hemodynamics and right ventricle hypertrophy.

Conclusions:

• A compensatory decrease in PRDC in hypertensive lungs may slow PAH progression.
• PRDC's role suggests potential therapeutic strategies for pulmonary arterial hypertension.
• Targeting PRDC could offer a novel approach to managing PAH.